1. Introduction {#S4}
===============

Although pain is one of the most common human experiences, the scientific discipline of pain research and the medical subspecialty of pain management are relatively new fields. Prior to the 1800s, pain was largely viewed as an existential experience and accepted as a consequence of aging ([@R68]), but the twentieth century saw the medicalization of pain management with a growth in the knowledge of pain pathophysiology and in the variety of pain treatment strategies. This paper will focus on chronic pain, as this is an emerging field with high public health importance, and will provide (1) a review of the etiology of chronic pain, (2) an overview of the history of chronic pain management -- including reasons behind the dramatic rise in opioids for the treatment of most chronic pain disorders, (3) an overview of non-opioid analgesic treatment strategies, and (4) guidance for future pain research needs.

To ensure consistency throughout this paper, it is important to first define chronic pain. Pain is "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage" ([@R43]). In this definition, pain is understood not just as a function of neuronal activity, but highlights the importance of higher-level cognitive processes that help interpret and define the pain experience for individuals. Pain is understood as an inherently subjective experience that does not require identifiable tissue damage to be clinically significant. Chronic pain is defined as pain that has lasted beyond the normal healing time for a given injury, operationalized as pain lasting \>3 months ([@R43]). For treatment purposes, chronic pain is further divided as associated with or not associated with a terminal illness (usually cancer).

2. The epidemic of chronic pain in the United States {#S5}
====================================================

2.1. Differences between acute and chronic pain {#S6}
-----------------------------------------------

A comprehensive review of the pain signaling pathway is beyond the scope of this review, but readers can reference reviews by [@R20] and [@R51] for more information. Acute pain has a clear evolutionary and life-sustaining purpose -- to bring attention to the occurrence of actual or potential tissue damage and to motivate the organism to remove itself from the cause of pain. Nociceptors are peripheral neurons whose main purpose is to detect painful stimuli, and can be stimulated by extremes in temperature (heat or cold), pressure, and/or chemicals most often released in the inflammatory response ([@R20]). For example, only when a temperature stimulus reaches a physiologically determined point (usually 43 °C in healthy individuals) does a cutaneous heat nociceptor fire an action potential to indicate pain ([@R98]). Nociceptors transmit action potentials to the spinal cord or brainstem, and then to the cerebral cortex and thalamus. Direct injury to nerves through trauma, surgery, or chronic illnesses like diabetes mellitus or alcohol use disorder can also result in pain through spontaneous nociceptor transmission without painful stimuli, enhanced pain facilitation or pathologic neuroplasticity ([@R21]).

The rate of nociceptor firing (interpreted as pain intensity) can be influenced by the level of painful stimulus but also by peripheral and central sensitization. Peripherally, nociceptors can be changed via inflammatory mediators or repeated stimulation to fire at a lower intensity of stimuli that would not normally be painful (e.g., temperatures below 43 °C) ([@R75]). Centrally, second-order neurons that transmit nociceptor input to the cortex and thalamus can also be sensitized to increase rate of firing by direct injury or ongoing inflammation ([@R14]; [@R92]). Lastly, neurons that originate from the periaqueductal gray and rostroventral medulla can amplify or decrease pain signaling ([@R73]).

Acute pain resolves after tissue healing in most individuals. However, certain persons progress from acute to chronic pain, known as pain chronification. Although the processes underlying chronification are not yet well understood, central nervous system changes to pain facilitation and inhibition (such as those mentioned above) are thought to play a role ([@R73]).

The rates of pain chronification vary based upon the type of acute pain (e.g., low back, post-surgical, diabetic neuropathy) ([@R73]). However, the most consistent predictors of chronification across most types of acute pain are social and psychological factors. For example, Chou and Shekelle ([@R17]) found that maladaptive pain coping behaviors and co-occurring psychiatric illnesses were two of the strongest baseline predictors of chronic back pain. Pain catastrophizing, a validated set of negative emotional/cognitive processes involving pessimism, perceptions of helplessness, and magnification of pain-related symptoms, is associated with pain chronification after surgery ([@R26]; [@R94]). Once developed, chronic pain may be considered a separate disease process that will need tailored interventions other than repair of the original injury to improve function. In that cure is rarely possible, a chronic disease approach is helpful in conceptualizing care of patients with chronic pain.

2.2. The prevalence of chronic pain {#S7}
-----------------------------------

Approximately 100 million adults in the United States are affected by chronic pain at any given time, with chronic low back pain and headaches the most commonly diagnosed conditions ([@R34]). There are known demographic factors that predispose a person to develop chronic pain. For instance, women are more likely to report chronic pain than men (34.3% vs. 26.7% in a nationally representative sample in the US) ([@R45]). In addition, the prevalence of chronic pain increases with age ([@R83]; [@R96]; [@R87]). Persons with lower annual household income have greater odds of reporting chronic pain compared to persons with higher annual income ([@R87]). Lastly, persons with mental illness ([@R67]) have greater odds of chronic pain compared to the general population without these disorders. Irrespective of these differences in chronic pain prevalence, the total health care costs for chronic pain treatment are estimated to range between \$560 to 635 billion per year in the United States, eclipsing the annual costs of heart disease, diabetes and cancer ([@R34]).

3. A history of chronic pain management: follow the money {#S8}
=========================================================

3.1. The beginning: multidisciplinary in nature {#S9}
-----------------------------------------------

John J. Bonica, an anesthesiogist, is widely considered to be the father of modern pain management. He was trained in an era of the "specificity theory of pain" that stated pain resulted from an identifiable injury. According to this perspective, correction of that injury (through surgery or rehabilitation) or blockade of the nociceptors in that area ("regional anesthesia") should provide complete pain relief. Dissatisfied with the results of his own management of chronic pain in soldiers using regional anesthesia during WWII, John Bonica began consulting with clinicians from different disciplines (e.g., neurology, psychiatry, and orthopedics) on difficult patients to improve analgesic response and functional outcomes. As he noticed an improvement in pain relief and function in this consultation practice, he developed the first multidisciplinary pain clinic based upon these experiences at Tacoma General Hospital in the 1950s. This clinic attempted to increase the efficiency of consultative practice and decrease patient burden by co-locating all staff members in the same space. He transferred the clinic to the University of Washington in Seattle in the 1960s ([@R8]) when he became chair of the Department of Anesthesia. Dr. Bonica's original clinic had inpatient and outpatient components.

The subsequent addition of operant conditioning methods from the psychologist Wilbert Fordyce allowed the clinic to provide marked improvements in patient self-management of pain ([@R32]). These methods included rewarding patient behaviors associated with improvement through positive staff feedback (e.g., improved exercise tolerance, increases in work and social activities) and extinction of "pain behaviors" (e.g., verbal or facial pain complaints, reliance on medications for pain management, and stopping exercise to sit) by administering medication on a schedule (as opposed to whenever a patient reported increased pain) and providing rest only after exercise regimens are completed (as opposed to when pain increases).

Over time, the pain community came together to provide guidelines to what constitutes a multidisciplinary pain treatment program. First, the clinic should be staffed with clinicians trained in pain management from various disciplines: at least two physicians, a pain psychologist, a physical therapist, and additional health care providers as needed to address unique patient populations served in the clinic (e.g., occupational therapist with knowledge about return to work evaluations) ([@R36]). Second, there should be regular meetings with all staff members present to discuss ongoing patient care issues. Third, assessment and treatment options should be comprehensive and include (at a minimum): physical exam, medication management, biopsychosocial evaluation, cognitive behavioral treatment for chronic pain, physical therapy, occupational therapy, and ability to refer to specialists not offered by the team. Fourth, the clinic team should be co-located in the same space and share a common philosophy of pain rehabilitation.

Due to improvement in overall patient functioning, reductions in health care expenditures and an increase in rate of patients returned to employment, the multidisciplinary pain clinic was deemed a success ([@R30]; [@R48]). In these published meta-analyses, multidisciplinary pain clinics were compared to single discipline treatment (e.g., physical therapy, medication management), usual medical care, and/or no treatment. Impressively, treatment gains remained evident for up to 13 years ([@R81]; [@R74]). Analyses of patient outcomes revealed that it wasn't any single component of the clinic treatment that led to improvements in pain outcomes, but rather an effect of the concerted biopsychosocial team approach ([@R54]; [@R84]). Subsequently, the number of pain clinics and accredited pain fellowship programs flourished, most of which used opioid therapy sparingly due to concerns of addiction and poor outcomes ([@R68]). These early clinics were multidisciplinary using similar methods to Bonica's original model, or clinics focused on a single pain syndrome (e.g., migraine headaches) or single treatment modality (e.g., providing nerve blockade or physical therapy) ([@R10]).

3.2. The peculiar fall of multidisciplinary pain clinics: money matters {#S10}
-----------------------------------------------------------------------

Several economic factors have been attributed to a decrease in the number of multidisciplinary pain clinics since the 1990s and an increase in the single modality, interventional and opioid-focused clinics. First, market forces emerged to reduce reimbursement rates for multidisciplinary clinics. Use of the American Medical Association's current procedural terminology (CPT) codes became necessary for reimbursement of most health services in the early 1980s. As CPT codes were originally designed to be used in medical charting to describe an intervention (e.g., an appendectomy), these codes inherently emphasized fee-for-service model of health care delivery, and ran counter to the multidisciplinary pain clinic model of providing a package of services -- all of which were necessary for optimal patient outcomes. Unless individual clinics contracted with payers (e.g., worker's compensation carriers, insurance carriers) to provide bundled services for enrollees, clinics had to bill for each service separately. Denials of claims became commonplace and threatened clinic solvency due to lengthy appeals processes.

The growth of managed care in the late 1980s and early 1990s led to "carving out" specific services in the multidisciplinary pain clinic, e.g., physical therapy would not be reimbursable if performed by therapists in the multidisciplinary pain clinic but needed to be performed by an alternate clinic across town. Subsequent studies showed worse pain treatment and decreased overall cost savings outcomes with this approach ([@R35]; [@R80]). For example, patients at one multidisciplinary pain treatment center who were required by insurance companies to attend off-site physical therapy had no significant improvements in overall pain level, pain related disability, or physical/mental functioning, compared to similar contemporaneous patients completing the full multidisciplinary treatment program on-site who achieved significant improvements in all of those realms.

Second, the academic medical centers that housed and often subsidized many of the multidisciplinary pain clinics became increasingly concerned with profits. Finite clinic space began to be allocated to programs with the highest profit margins (e.g., plastic surgery, orthopedics, or cardiology), at the expense of multidisciplinary pain treatment programs, which brought in significantly less revenue after the advent of managed care ([@R84]).

Third, as pain fellowship physician training programs developed, they came to be recognized as a subspecialty under anesthesiology, thus training and accreditation bodies placed more emphasis on proficiency in procedure-based care (e.g., nerve blocks, ablations, and insertions of spinal cord stimulators -- please see below) than being a member of a multidisciplinary care team. This is reflected by the training curriculums and certifying examinations ([@R1]). As a result, increasing numbers of pain fellowship graduates were prepared for and sought employment performing procedures in often highly lucrative modality specific pain clinics. As a result of all these forces, many of the multidisciplinary pain treatment clinics established in the 1970s and 80 s closed due to financial concerns -- leaving the majority of chronic pain care in the hands of primary care providers and modality specific chronic pain treatment clinics.

3.3. Pain as the "Fifth Vital Sign" {#S11}
-----------------------------------

Since the passage of the Harrison Narcotic Act in 1914, physicians and patients alike had been afraid of developing addiction if placed on morphine or other opioids ([@R68]). Therefore, opioids were used sparingly in the treatment of chronic pain; in addition to addiction, concerns of tolerance limiting analgesic efficacy contraindicated their use for treating chronic pain. However, there was increased recognition that many terminal patients lived out their last days in agonizing pain. Specialists in palliative care, such as Kathleen Foley and her fellow, Russell Portenoy, at Memorial Sloan Kettering recognized the relief that opioids brought to dying cancer patients through extensive clinical experience in the 1970s and 80 s ([@R31]; [@R76]). Concurrently, the World Health Organization developed cancer pain treatment guidelines that included opioids for the first time and recognized the treatment of pain as a universal right ([@R102]; [@R56]).

Shortly thereafter, the American Pain Society (APS) initiated an influential campaign, "Pain, The Fifth Vital Sign," to raise awareness among health professionals of pain assessment and management. Although opioids were described as just one possible treatment option, the initiative did advocate a change in philosophy around use of opioids for chronic pain. Opioids were promoted as a way to improve quality at end of life. The Veteran's Health Administration (VHA), the largest government run health-care system in the US, adopted pain as the 5th vital sign initiative in 1999--giving strong credibility to the campaign ([@R71]).

By the late 1990s, it was generally accepted that all patients are entitled to the assessment and treatment of pain, resulting in influential regulatory bodies such as the Joint Commission on the Accreditation of Healthcare Organizations (JCAHO) mandating pain assessment and treatment of all patients in accredited health care settings by 2001 in order to receive federal health care dollars ([@R60],[@R61]; [@R2]). The Federation of State Medical Boards made a clear statement in 1998 that physicians would not receive excessive regulatory scrutiny if prescribing notable amounts of opioids -- a fear that had previously reduced the willingness of physicians to prescribe opioids for chronic pain ([@R46]). The Drug Enforcement Agency (DEA) in 2001 also agreed to follow a "balanced policy" in examining prescribing practices that would encourage use of opioids to relieve pain and reduce oversight of physicians that had high rates of opioid prescribing.

Although the APS campaign led to increases in pain research, education, and an important focus on pain relief, there have been unintended consequences resulting in an overreliance on opioids to treat chronic non-malignant pain. Health care providers accredited by the JCAHO were mandated to implement adequate pain assessment and treatment methods for all patients in a relatively short period of time (2 years). Although specific analgesic treatments (non-pharmacologic and pharmacologic) were left up to the individual physician or provider, these health care facilities developed policies that liberalized the use of opioids in an attempt to meet JCAHO standards. In addition, as patient satisfaction (including pain relief) became an increasingly valued health care outcome, clinicians in these facilities were further encouraged to use opioids to control pain quickly and as completely as possible. Although higher opioid use remains a theoretical risk of rewarding patient satisfaction scores ([@R105]), a national study showed health care facilities that have highest patient satisfaction scores reported greater expenditures on prescription drugs then those with lowest satisfaction scores ([@R28]).

During the 1990s and early 2000s, provider and patient fears of addiction to prescribed opioids were minimized due to an overemphasis on the findings of two small retrospective studies which suggested that patients rarely develop opioid use disorder when opioids were prescribed for the treatment of pain ([@R78]; [@R76]). The first was a letter that suggested very low (0.03%) addiction rates in hospitalized patients provided doses of opioids for acute, non-recurrent pain ([@R78]). The second reported on 38 patients from one practice prescribed opioids for chronic non-malignant pain ([@R76]), and showed only 2 patients (5.3%), both with history of substance use disorder, developed management problems (dose escalation and diversion, respectively). These reports became heavily cited in peer-reviewed and non-peer reviewed literature ([Fig. 1](#F1){ref-type="fig"}); the reports were also incorporated into training of new physicians, nurses, dentists and other health care providers. However, these early claims of low addiction risk when generalized to chronic pain management were based upon insufficient evidence as history has shown.

3.4. Opioid prescribing skyrockets {#S12}
----------------------------------

Related to the historical shifts outlined above, the treatment of chronic non-cancer pain became a new and growing indication for an opioid prescription. Most famously, Purdue Pharmaceuticals introduced Oxycontin^®^ (oxycodone extended release) in 1996, which was marketed aggressively with FDA-approved labeling to claim that iatrogenic addiction was "very rare" and "delayed absorption of OxyContin was believed to reduce the abuse liability of the drug" ([@R97]). This resulted in an exponential increase in the number of Oxycontin prescriptions from 670,000 in 1997 to about 6.2 million in 2002, when the label was changed to drop the above language. Despite the change in label and a lawsuit judgment for over \$630 million for continuing to claim falsely that OxyContin was less addictive than other opioids, US sales of Oxycontin continued to be close to 6.5 million prescriptions annually until August 2010 when a reformulated "abuse deterrent" Oxycontin was brought to market ([@R42]). As with Oxycontin, prescriptions for all opioids increased dramatically throughout the late 1990s and 2000s. Opioid prescriptions were frequently written by practitioners without specialty training (including dentists), and in a few rare cases, by providers who focused on writing opioid prescriptions for profit.

3.5. Does chronic opioid therapy improve treatment outcomes? {#S13}
------------------------------------------------------------

At present, there is no conclusive answer to the above question. A systematic review was completed in preparation for the 2016 CDC guidelines on the use of opioids for the treatment of chronic non-malignant pain in primary care. The review inclusion criteria specified studies of opioid analgesic effectiveness must have \>12 months of follow-up and be compared to a non-opioid control, but studies of opioid harms could be uncontrolled and have any length of follow-up. As a result, no controlled studies on opioid effectiveness met inclusion criteria but 19 studies (mostly uncontrolled studies using claims databases) were included that examined harms. The review concluded that there were no well-controlled long-term studies indicating that opioid treatment for pain beyond twelve weeks effectively relieves pain or improves function ([@R19]). These clinical trials focused mainly on pain relief and did not typically report on other pain related outcomes, including quality of life, reduction in disability, or return to work. In contrast, there are multiple reports in the peer-reviewed literature from single-arm observational studies, open label designs and case reports that include hundreds of individuals maintained on chronic opioid therapy (\>12 months) for a variety of pain diagnoses that saw sustained improvement in pain levels ([@R104]; [@R70]; [@R4]; [@R13]; [@R66]; [@R77]). Thus, despite the lack of controlled long-term studies \>12 weeks, there is clinical consensus from pain management practitioners that some patients do well on chronic opioids ([@R18]). Given the discrepancy between systematic reviews of controlled studies and clinical consensus, there is no clear answer on whether chronic opioid therapy can improve pain level, pain-related disability, or quality of life in patients. In addition, it is important to include in a balanced perspective that chronic opioid therapy is associated with overdose death, development of substance use disorder, fractures, and sexual dysfunction ([@R19]).

4. Effective pain management strategies: beyond prescription opioids {#S14}
====================================================================

An unfortunate consequence of the recent focus on prescription opioids to treat chronic pain has been a lack of research on, and clinical attention to the efficacy of a wide variety of non-opioid chronic pain management strategies. The primary goals of chronic pain management are discovering a cause, alleviating suffering, and restoring function. Biologic, psychological, and social factors all play a role in the perception and chronification of pain and each should be assessed and managed as needed. As previously reviewed, strong consensus supported by meta-analytic reviews affirms that a multidisciplinary rehabilitation approach to the treatment of chronic pain is more effective compared to single modality/single practitioner treatment options ([@R30]; [@R48]; [@R85]) However, this treatment option is not widely available. Therefore, the following section outlines various treatment approaches to better assist the reader in understanding the wide array of other chronic pain treatment options. Included are opioid and non-opioid pharmacotherapies, physical therapy, psychological and behavioral therapies, complementary and alternative medicine strategies, peripheral procedures, spinal procedures, and surgery ([Table 1](#T1){ref-type="table"}). As with opioid clinical trials, controlled trials of non-opioid analgesic strategies are typically short (\< 12 weeks) and so long-term effectiveness data for chronic pain using these strategies is limited ([@R93]).

4.1. Non-opioid pharmacotherapies {#S15}
---------------------------------

There are numerous medications used to treat chronic non-malignant pain that target the mechanisms of peripheral and central sensitization, the proposed mechanisms contributing to pain chronification, e.g., sodium and calcium channel upregulation, spinal hyperexcitability, descending modulation and loss of inhibitory interneurons. Aspirin, acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDS; e.g., ibuprofen or naproxen) are the first choice in the pharmacological management of acute pain ([@R9]), but can also be useful in the management of mild to moderate chronic pain as single agents or as a component of multimodal pain control in severe chronic pain ([@R27]). NSAIDs are more effective in the treatment of chronic musculoskeletal pain (e.g., osteoarthritis, chronic non-specific low back pain) compared to neuropathic pain. In addition, naproxen has been FDA approved for pain associated with ankylosing spondylitis, an inflammatory autoimmune disorder that causes the vertebrae of the spine to fuse together. Significant side effects of NSAIDs include bleeding, Stevens-Johnson syndrome, and renal failure. Long-term use is not recommended unless under the care of a physician or other prescriber.

Antidepressants and anticonvulsants are frequently used in the treatment of chronic neuropathic pain ([@R65]; [@R6]; [@R29]). The analgesic effects of antidepressants are thought to be independent of their antidepressant effects, as persons without current major depressive disorder receive significant analgesic benefit ([@R57]). Duloxetine is the only antidepressant to have FDA approval for the treatment of chronic pain (diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain), although antidepressants with dual serotonin and norepinephrine reuptake inhibition are used off-label to provide pain relief ([Table 1](#T1){ref-type="table"}). Prescribers should watch for the development of new suicidal thoughts, hyponatremia, serotonin syndrome, and hepatitis/liver failure while using anti-depressants, and patients should be counseled that pain relief often occurs slowly over time (usually 4--6 weeks after reaching an effective dose). Anticonvulsants reduce pain by inhibiting excessive neuronal firing, including nociceptors. First and second generation anticonvulsants (e.g., gabapentin and pregabalin) are FDA approved for the treatment of a variety of neuropathic conditions including diabetic neuropathy, trigeminal neuralgia, and post-herpetic neuralgia ([@R57]). As with anti-depressants, patients should be counseled that pain relief may take 4--6 weeks to occur and monitored for the development of new-onset suicidal ideation, sedation leading to falls, hypoglycemia, and acute renal insufficiency ([Table 1](#T1){ref-type="table"}). There is also increasing evidence that patients may misuse or abuse gabapentin ([@R16]; [@R89]).

4.2. Physical therapy (PT) {#S16}
--------------------------

Reductions in pain related to medications and invasive procedures can enable patients to fully participate with PT, which has an important role in pain relief and restoration of function in chronic pain patients ([@R50]). PT should strongly be considered for the management of chronic pain to gradually increase flexibility and strength, for example in knee osteoarthritis where there is demonstrated benefit ([@R33]). A referral from a physiatrist, primary care physician or nurse practitioner is often required before initiating PT. Although initially therapist-directed, PT can become self-directed over time. A course of PT usually requires an intake assessment and 8--12 PT sessions over the course of 4--6 weeks. Techniques include stretching exercises, manipulations, hot or cold applications, traction, transcutaneous electrical nerve stimulation (TENS), and massage. Risks of PT include myocardial infarction leading to sudden death, as well as worsening pain (especially at beginning of treatment).

4.3. Psychological and behavioral therapies {#S17}
-------------------------------------------

Many psychological and behavioral therapies have been used in the treatment of pain and its associated disability and distress -- irrespective of the presence or absence of mental illness ([@R25]). Cognitive-behavioral therapy (CBT) is an effective approach based on the theory that beliefs, attitudes, and expectations affect emotional and behavioral reactions to life experiences, including pain. Patients are taught to be active participants in the management of their pain with the goals of increasing activity, independence, and resourcefulness. Persons with high levels of pain catastrophizing may especially benefit from psychological and behavioral therapies ([@R88]). CBT usually requires 12 weeks of treatment to see maximum benefit, with hour-long weekly individual sessions with a therapist and homework to be completed outside of sessions. A referral is often needed, and the availability of pain-informed CBT therapists is a problem for many patients. Unfortunately, a systematic review found that pain relief that occurred after CBT does not persist long-term ([@R100]).

A recent randomized clinical trial has also shown the promise of mindfulness based stress reduction (MBSR) as a treatment for chronic pain ([@R15]). MBSR is usually provided in group sessions lasting 2 h weekly for up to 8 weeks. Patients are also asked to practice MBSR techniques at home in between sessions. Pain relief tends to be short-term but improvements in physical functioning have been maintained up to 26 weeks of follow-up ([@R15]). MBSR therapists do not require masters or doctoral level training in counseling/psychology. However, specialized training is required, and insurance does not typically cover MBSR.

4.4. Complementary and alternative medicine (CAM) {#S18}
-------------------------------------------------

Increasingly, patients are turning to pain interventions that are not commonly taught in medical training and are less often covered by insurance payers. CAM treatments include acupuncture, manipulation, vitamins and supplements (fish oil, capsaicin, glucosamine), yoga, music therapy, biofeedback, and hypnosis. Other than acupuncture and spinal manipulation, these strategies have been less rigorously studied in clinical trials and little is known about the long-term benefits or harms ([@R72]). Acupuncture is a part of traditional Chinese Medicine that involves the stimulation of specific parts of the body through the use of needles. Acupuncture has been used for pain management for two thousand years in China. Recently, electrical currents have been added to further stimulate the needles in electroacupuncture, although manual acupuncture without electrical current is the most commonly used method. The exact analgesic mechanism for acupuncture is not known, although growing evidence points towards acupuncture needles stimulating mechanoreceptors, which triggers a release of endorphins and increased activity of the descending inhibitory pain pathways ([@R52]). Although acupuncture has been used to treat a wide variety of pain syndromes (e.g., osteoarthritis, chronic pelvic pain, fibromyalgia, chronic low back pain), systematic reviews revealed mostly short-term benefits. In patients with osteoarthritis, acupuncture can improve physical functioning that is maintained over follow-up but does not provide significantly greater pain relief compared to sham acupuncture in long-term follow-up ([@R53]). In addition, no long-term follow up studies have demonstrated that acupuncture provides greater pain relief for chronic neck pain or chronic nonspecific low back pain compared to sham acupuncture but short-term pain relief is superior comparing active to sham acupuncture ([@R103]; [@R95]). Acupuncture is superior to sham acupuncture for reducing pain from chronic prostatitis/chronic pelvic pain syndrome, although long-term follow-up studies are lacking. ([@R55]).

Spinal manipulation are treatments that "use high velocity/low amplitude to move a joint that is exhibiting somatic dysfunction through its restrictive barrier" ([@R82]). Typically, chiropractors perform spinal manipulations although doctors of osteopathic medicine are also trained in these treatments. There is no consensus on the exact procedure for spinal manipulation, and insurance does not often cover them. In a recent meta-analysis of sham controlled RCTs, there was evidence that spinal manipulation improved pain ratings post-treatment and in 1 month follow-up compared to sham in patients with chronic non-specific low back pain ([@R82]). However, there have been no well-controlled long-term follow-up studies to demonstrate if these improvements are lasting. In addition, adverse events are not always reported in RCTs of spinal manipulation, so weighing risks versus benefits is challenging ([@R39]).

4.5. Invasive pain management interventions: peripheral procedures, spinal procedures, and surgery {#S19}
--------------------------------------------------------------------------------------------------

Invasive treatments that are used for the management of chronic pain include injections of local anesthetics and steroids, peripheral procedures, electrical stimulation, and surgery ([@R60],[@R61]), which are typically provided by anesthesiologists, neurosurgeons, physiatrists, and other physicians trained in pain medicine ([Table 1](#T1){ref-type="table"}). The growth of interventional pain medicine (as described in Section 3) has shown dramatic growth in utilization of invasive pain management interventions. ([@R62]), although, as described below, evidence of efficacy is often lacking.

Peripheral procedures include trigger point injections and intraarticular injections. Trigger point injections involve dry needling into the muscle tissue to induce a localized twitch response and subsequent ending of contracture ([@R38]). A recent systematic review showed that dry needling decreases pain immediately post-treatment compared to sham, and may result in pain relief lasting 3--6 months ([@R11]). Injection of lidocaine or corticosteroid is also performed in some trigger point injections, although medication injection is not thought to improve upon dry needling ([@R22]; [@R11]). For arthritic pain related to cartilage loss, intra-articular injections are performed with either a corticosteroid to reduce inflammation or sodium hyaluronate to form a viscoelastic solution that serves as a protective buffer between joints. Despite the lack of evidence from systematic reviews ([@R5]; [@R59]; [@R47]; [@R101]; [@R64]), intraarticular injections continue to be performed (often repeatedly) in at least a third of Medicare patients with knee osteoarthritis ([@R49]).

Spinal procedures are intended to interrupt the pain signaling pathway and include epidural injection of anesthetic (nerve blocks) +/− steroids, radiofrequency denervation, and insertion of spinal cord stimulators. Systematic reviews have not shown significant benefit of epidural steroid injections over standard treatment in chronic low back pain from any cause ([@R91]). Nerve blocks (involving epidural injections of lidocaine without steroids), however, do provide significant pain relief for lumbar radicular pain or pain from spinal stenosis compared to steroid injections ([@R63]). Radiofrequency ablation uses electrical heat to produce a lesion in a pain-transmitting nerve, thereby blocking pain transmission and providing pain relief ([@R86]). Systematic reviews have not demonstrated significant long-term pain relief with ablation compared to sham treatments, but may provide short-term pain relief for facet joint related pain ([@R58]). Electrical stimulation of the spinal cord occurs through an implanted device using low voltage electrical impulses to block pain transmission ([@R90]), consistent with the gate control theory of pain ([@R69]). Although pain relief can be significant in patients with few other options, there is a relatively high complication rate from this procedure (35% in a recent retrospective study ([@R41])) and ongoing device management is required.

Surgical interventions are usually reserved for patients that have failed to respond to more conservative measures or when there would be irreversible neurological damage without emergent surgical intervention (e.g., disc herniation, spinal stenosis) ([@R23]). Scar tissue and adhesions can worsen the pain over time, and re-injury can occur ([@R12]). Therefore, a lengthy recovery time is recommended to ensure re-injury does not occur.

5. The provider's dilemma: how to best treat chronic pain {#S20}
=========================================================

A health care provider must often make clinical decisions based upon insufficient evidence, despite the call to evidence-based practice exclusively. In the case of chronic pain treatment, there are risks and benefits associated with each treatment option but little long-term (\>12 months) follow-up data. In addition, patients must consider, the practicalities of time required for each treatment, whether or not insurance covers the particular modality, and whether there are available providers who are licensed and taking new patients in the area. The importance of effectively treating pain is underscored by the increased odds of suicide, major depressive disorder, substance use and substance use disorders seen in chronic pain patients compared to persons without chronic pain ([@R7]; [@R37]; [@R40]; [@R3]). In addition, there is evidence that untreated pain can also lead to relapse in patients with prior history of substance use disorders ([@R99]).

In the face of moral, ethical, legal and regulatory pressures to relieve suffering, writing a prescription, especially for opioids, has become the quickest and least expensive (to the patient) option in the US health care system for individuals seeking traditional medical treatment for chronic pain. Any physician, nurse practitioner, or physician assistant can prescribe opioids as long as he or she has the appropriate DEA and state practice license (exact guidelines differ between each state), and prescription opioids are almost universally covered by insurance. However, guidelines from various professional societies and governmental agencies provide conflicting recommendations on the use of opioids for chronic non-cancer pain ([@R18]; [@R24]), so the provider is left with a difficult decision of whether or not to prescribe them.

If opioids are no longer the preferred chronic pain management strategy and there is a lack of multidisciplinary pain treatment centers, the primary care provider must overcome many hurdles to develop a multimodal treatment approach for each patient. Physical, psychological and behavioral therapies can be burdensome to the patient, requiring frequent (usually weekly or more) visits, as well as individual practice using techniques/exercise away from the clinic. Although usually covered by insurance, these often have higher out-of-pocket expenses compared to prescription opioids, and limits on number of yearly visits -- especially with psychological interventions. Pain relief usually takes time to manifest with PT, psychological and behavioral therapies, unlike immediate relief as after prescription opioid administration. Experience of the practitioner can vary, such that not every therapist is trained in pain or participates with an individual's insurance plan. Other system barriers include need of referral, availability of licensed providers (including health behaviorists), time off from work, lack of childcare, and availability of transportation. In addition, patients may be hesitant to agree to psychological interventions due to perceived stigma or religious/cultural biases ([@R44]).

Lastly, although single modality pain treatment centers are very frequent, there are geographic variations with rural areas having fewer practitioners. Additionally, practitioners may not have the expertise to perform the more complex procedures, such as insertion of spinal cord stimulator. These procedures also require insurance prior-authorization, and spinal cord stimulator insertion requires a psychological evaluation prior to procedure. In the current US health care system and with a limited evidence base, there are no easy solutions for providers to effectively treat chronic pain patients using a multimodal approach.

6. Future directions {#S21}
====================

As the use of opioids for the treatment of chronic pain undergoes increasing scrutiny, the next generation of pain treatment strategies is needed to take their place. It is doubtful, however, if the approximately 5--8 million individuals currently prescribed opioids for chronic pain are going to suddenly stop or taper easily ([@R79]). Although calls for responsible opioid prescribing will grow, there will certainly be opioid prescribing at high levels for years to come. In addition, then, to the existing data showing efficacy for multidisciplinary pain treatment approaches absent opioid pharmacotherapy, there is a new set of questions that will need to be answered to inform pain treatment of the future. **What is the safety and efficacy of opioid medications used for the treatment of chronic non-cancer pain for periods \>1 year?** Data on longer-term outcomes from studies on the efficacy and risks of opioid therapy for chronic non-malignant pain are lacking. It is important to understand the conditions under which long-term benefits of pain relief might be observed and how the pain relief may change over time. It is also important to understand whether the risks of chronic exposure, especially addiction and physical dependence, are modulated by any long-term benefits of pain relief. An understanding of patient pain syndrome and medication-specific risk factors for both good and poor outcomes is also needed. It would be very helpful to enroll both persons with and without substance use disorders into future long-term studies.**What are the system specific needs and barriers for the utility of non-opioid therapies for the treatment of chronic pain?** Noted throughout this review is that access to potentially effective non-medication interventions is often limited by current models of health service reimbursement. New research strategies such as comparative efficacy and factorial design trials could provide useful guidance on the best and most cost-effective approaches to pain management in individuals with different characteristics and types of chronic pain. Funding for these studies should come from government and industry partnerships.**What is the role of opioid pharmacotherapy in combination with non-opioid therapies in chronic pain management?** If research shows that long-term use of opioids is useful at least for some types of pain patients, then this approach will need to be examined in interaction with other non-opioid therapies to determine optimal combination strategies.

This is an ambitious research agenda. However, given the debilitating effects of chronic pain, the numbers of individuals involved and the cost to society, it would appear to be a timely and useful undertaking. Clinicians continue to have an ethical and legal obligation to assess and treat pain. Therefore, research is urgently needed to increase the evidence base of chronic pain management so that we can begin the post-"opioid-opioid-opioid" era in pain management while improving outcomes and functionality for patients.
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Common non-opioid chronic pain management strategies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Strategy                                                        Examples                                                             Usual Dose Range                                                                                 FDA Approved Chronic\                                                                                                                                           Significant Side Effects                                                                                                                               Notes
                                                                                                                                                                                                                                        Pain Indications                                                                                                                                                                                                                                                                                                       
  ---------------------------------- ---------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Multidisciplinary pain treatment                                Johns Hopkins Hospital Pain Treatment Program                        3--4 weeks of intensive 5--7 days/week attendance at clinic                                      Not subject to FDA approval. Has been shown to improve any type of chronic pain, especially with no identifiable cause or where other approaches have failed.   None                                                                                                                                                   Patient should be willing to decrease/stop opioid medications. Insurance coverage may not be available or require significant prior authorization process.

  Non-opioid medications             NSAID                        aspirin                                                              325 to 650 mg every 4 h (Max 4 g/day)                                                            Disorders of joint of spine, generalized pain, headaches, OA, RA                                                                                                Bleeding, gastric ulcer, tinnitus, bronchospasm, and Reye's syndrome                                                                                   Should not take OTC aspirin for more than 10 days at a time without instruction from physician.

                                                                  ibuprofen                                                            200 to 800 mg every 4--6 h (Max 3.2 g/day)                                                       Generalized pain, headaches, OA, RA                                                                                                                             Congestive heart failure, myocardial infarction, stroke, Stevens-Johnson syndrome, and hearing loss                                                    Should not take OTC ibuprofen for more than 10 days at a time without instruction from physician.

                                                                  naproxen                                                             250 to 500 mg every 12 h (Max 1 g/day)                                                           Ankylosing spondylitis, bursitis, generalized pain, OA, RA                                                                                                      Congestive heart failure, myocardial infarction, stroke, Stevens-Johnson syndrome, bleeding, and renal failure                                         OTC naproxen can be taken for 6 months without instruction from physician.

                                     Anti-depressants             duloxetine                                                           30 to 60 mg daily                                                                                Diabetic peripheral neuropathy, fibromyalgia, chronic musculoskeletal pain                                                                                      May be fatal in overdose, suicidal ideation, Stevens-Johnson syndrome, myocardial infarction, liver failure, and serotonin syndrome                    Cannot be stopped suddenly or may have withdrawal syndrome. Pain relief may take 4--6 weeks after achieving an effective dose.

                                                                  venlafaxine                                                          75 to 225 mg daily                                                                               None.                                                                                                                                                           Hyponatremia, bleeding, hepatitis, seizure, suicidal thoughts, and serotonin syndrome                                                                  RCTs have demonstrated efficacy for neuropathic pain and prophylaxis of migraine/tension type headaches. Pain relief may take 4--6 weeks after achieving an effective dose.

                                                                  nortriptyline                                                        50 to 100 mg daily                                                                               None.                                                                                                                                                           Sudden cardiac death, SIADH, hepatic failure, stroke, suicidal thoughts, dizziness, and falls                                                          Dosing should be guided by plasma blood level. RCTs have shown efficacy for neuropathic pain. Pain relief may take 4--6 weeks after achieving an effective dose.

                                     Anti-epileptic drugs         gabapentin                                                           300 to 600 mg every 8 h                                                                          Post-herpetic neuralgia                                                                                                                                         Stevens-Johnson syndrome, hypoglycemia, sedation, suicidal thoughts, dizziness, and falls. Misuse and/or abuse of gabapentin has also been reported.   RCTs have also shown efficacy for diabetic peripheral neuropathy, and fibromyalgia. Pain relief may take 4--6 weeks after achieving an effective dose.

                                                                  pregabalin                                                           75 to 150 mg every 12 h (Max 450 mg/day)                                                         Diabetic peripheral neuropathy, fibromyalgia, neuropathic pain from a spinal cord injury, post-herpetic neuralgia                                               Jaundice, suicidal thoughts, and acute renal insufficiency                                                                                             Pain relief may take 4--6 weeks after achieving an effective dose.

  Physical therapy (PT)                                           Exercise therapy                                                     8--12 PT sessions over 4--6 weeks                                                                Not subject to FDA approval. Used to treat back and neck pain, arthritis, fibromyalgia                                                                          Worsening pain, new injury, myocardial infarction, and sudden death                                                                                    Referral is needed. Patient needs to practice skills at home. Exercises are widely variable by therapists.

  Psychological therapies                                         CBT                                                                  Weekly hour-long individual sessions for 12 weeks                                                Not subject to FDA approval. Used for all types of pain.                                                                                                        None                                                                                                                                                   Referral may be needed. Patients need to complete homework. Pain relief is only short-term. Not all therapists trained in pain CBT.

                                                                  MBSR                                                                 Weekly 2-h long group sessions for 8 weeks                                                       Not subject to FDA approval. Used for all types of pain.                                                                                                        None                                                                                                                                                   Optional 6-h retreat. Instructors for MBSR are not widely available. Pain improvement is short-term but can improve physical functioning for up to 26 weeks.

  CAM                                                             Acupuncture                                                          6--12 weekly sessions over 6--12 weeks                                                           Not subject to FDA approval. Used to treat OA, chronic pelvic pain, chronic prostatitis, chronic neck pain, chronic back pain                                   Nerve injury causing worse pain and infection                                                                                                          Not always covered by insurance or available; no widely accepted protocol of acupuncture delivery; most studies performed outside USA

  Peripheral procedures              Trigger point injections     Lidocaine, corticosteroid, or "dry needling"                         Single injection by physician. May be repeated.                                                  Not subject to FDA approval. Used to treat chronic neck pain, headaches, iliac crest syndrome, and myofascial pain.                                             Nerve injury causing worse pain, infection, pneumothorax, seizure, and local tissue necrosis                                                           Need to palpate location of maximum tenderness. Few long-term studies. Should be done with PT.

                                     Intra-articular Injection    Sodium hyaluronate, corticosteroid                                   Single Injection by physician. May be repeated.                                                  Not subject to FDA approval. Used to treat OA, RA, hip arthritis, low back pain, shoulder pain, TMJ, de Quervain's tenosynovitis                                Nerve injury causing worse pain and infection                                                                                                          1--2 office visits. No clear evidence that these injections provide greater pain relief compared to sham procedures.

  Spinal procedures                  Epidural steroid injection   Corticosteroid +/− local anesthetic (see nerve block for examples)   1--3 injections separated by at least a month (no more than 3 injections in 12 months)           None.                                                                                                                                                           Infection, bleeding, vertebral fracture (after multiple injections), paralysis, stroke, loss of vision and death.                                      Best results use fluoroscopic guidance. Multiple different procedures to enter epidural space. No clear evidence that these injections provide greater pain relief compared to sham procedures.

                                     Nerve block                  0.25%-0.5% bupivacaine, 2% lignocaine, or 1% lidocaine               One diagnostic block and then second long-term nerve block (3--6 months pain relief).            Chronic radiculopathy, cancer- related, facet join degeneration                                                                                                 Nerve injury causing worse pain, infection, paralysis, and seizure                                                                                     Outpatient surgical procedure. May repeat every 6--12 months as needed

                                     Radiofrequency denervation                                                                        1--2 diagnostic nerve blocks followed by fluoroscopic guided destruction of nerve                Facet joint pain, low back pain with disc herniation, sacroiliac pain.                                                                                          Nerve injury causing worse pain, infection, and paralysis                                                                                              Outpatient surgery. May be repeated. Systematic reviews of trials have not shown significant benefit over sham.

                                     Spinal cord stimulator                                                                            Insertion of temporary stimulator to determine efficacy and then insertion of permanent device   Chronic intractable pain of the trunk and/or limbs, pain associated with failed back surgery syndrome, complex regional pain syndrome                           Nerve injury causing worse pain, infection, and paralysis                                                                                              Pre-op psychological evaluation, at least two outpatient surgery visits, regular follow-up. Revisions may be necessary.

  Surgery                            Discectomy, spinal fusion                                                                                                                                                                          Back pain with nerve injury (e.g. disc herniation), spinal stenosis,                                                                                            Failed back surgery syndrome, death, paralysis, and infection                                                                                          Pre-op evaluation, surgery, +/− post-op hospital stay, usually 6 weeks off work, at least 3 month healing time, +/− PT
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NSAID = non-steroidal anti-inflammatory drugs; FDA = Food and Drug Administration; OTC = over the counter; CAM = complementary and alternative medicine; RCT = randomized clinical trials; CBT = cognitive behavioral therapy; MBSR = mindfulness based stress reduction; OA = osteoarthritis; RA = rheumatoid arthritis; SIADH = syndrome of inappropriate antidiuretic hormone secretion. These strategies are not mutually exclusive and can be combined as directed by a health care provider. Unfortunately, little information is known about the comparative effectiveness of these strategies.
